Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Japan Regulatory Update: More In-Depth Data Demands; Single-Audit Participation

This article was originally published in The Gray Sheet

Executive Summary

Japan's regulatory authority plans to establish a new Regulatory Science Centre in the next three years, which will be tasked with reviewing more in-depth data to support product approvals. Also, the country is now a full participant in the Medical Device Single Audit Program.

You may also be interested in...



10 Things You Should Know About The Medical Device Single-Audit Pilot

After a long build up, four international regulatory authorities officially rolled out the Medical Device Single Audit Program pilot this month. Here are 10 things companies should know about the program.

Pipeline Watch: Six Approvals And 15 Phase III Updates

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Lupin Bags First US Rival To $1.6bn Ingrezza – But Launch Will Have To Wait

Lupin has claimed the first US approval for an Ingrezza generic – but must wait well over a decade before launching its version of valbenazine, after last year striking a patent litigation settlement with originator Neurocrine Biosciences.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT034052

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel